Rimegepant Meets Primary End Point in Episodic Migraine

Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group.

Source link

Related posts

Why the Discovery of ‘LATE’ Dementia Is Important


The Connection Between Sleep & Back Pain


Green Light Therapy and Migraines: Will Research Translate to Real-World Use?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy